Left ventricular mass regression after two alternative sutureless aortic bioprostheses.

Area of Science:

• Cardiology
• Cardiac Surgery
• Biomedical Engineering

Background:

• Left ventricular (LV) hypertrophy in aortic stenosis (AS) is a significant risk factor for cardiac morbidity and mortality.
• Aortic valve replacement (AVR) is a standard treatment for symptomatic AS.
• Sutureless bioprostheses offer potential advantages in AVR procedures.

Purpose of the Study:

• To compare the degree of LV mass regression after AVR using two sutureless self-expanding bioprostheses: Perceval S and 3f Enable.
• To evaluate the clinical outcomes and echocardiographic changes at 6-month follow-up.

Main Methods:

• A prospective study involving 129 patients with symptomatic AS undergoing AVR.
• Analysis of 45 patients receiving Perceval S and 19 patients receiving 3f Enable for isolated AVR.
• LV mass calculated using the Devereux formula, indexed to body surface area, with 6-month follow-up.

Main Results:

• No significant baseline differences between the Perceval S and 3f Enable groups.
• Mean LV mass index decreased significantly in both groups (P < 0.001 for Perceval S, P = 0.003 for 3f Enable).
• No significant difference in LV mass regression between the two bioprostheses (P = 0.315), with significant clinical improvement observed.

Conclusions:

• AVR with sutureless bioprostheses leads to significant LV mass regression at 6 months in isolated AS.
• Perceval S and 3f Enable demonstrate comparable efficacy in LV mass regression.
• Long-term echocardiographic evaluation is recommended to assess sustained regression.